Travere Therapeutics (TVTX) EBT Margin (2014 - 2026)
Travere Therapeutics (TVTX) reported EBT Margin of 28.87% for Q1 2026, up 2152.0% on a YoY basis from 1.28% in Q1 2025, and down 582.06% quarter-over-quarter from 5.99% in Q4 2025.
Travere Therapeutics (TVTX) EBT Margin (2014 - 2026) Analysis & Trends
Travere Therapeutics has reported EBT Margin for 13 years, with the latest figure at 28.87% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 2152.0% year-over-year to 28.87%; the trailing twelve-month figure through Mar 2026 stood at 63.93% (up 14653.0% YoY), and the FY2025 full-year result was 529.82%, down 39236.0% from the prior year.
- EBT Margin for Q1 2026 stood at 28.87%, down from 5.99% in the prior quarter.
- The five-year high for EBT Margin was 64.28% in Q3 2025, with the low at 348.94% in Q1 2022.
- Historically, EBT Margin has averaged 172.31% across 5 years, with a median of 196.47% in 2023.
- Annual changes were most pronounced in 2022 — EBT Margin sank 34777 bps — and 2025, when it soared 27775 bps.
- Travere Therapeutics' EBT Margin stood at 291.67% in 2022, then surged by 33 bps to 196.47% in 2023, then soared by 59 bps to 80.68% in 2024, then surged by 107 bps to 5.99% in 2025, then tumbled by 582 bps to 28.87% in 2026.
- The last three EBT Margin figures came in at 28.87% (Q1 2026), 5.99% (Q4 2025), and 64.28% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Travere Therapeutics | 5.07 Bn | 4.99 Bn | 102.38 Mn | -28.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.87% |
| Dec 31, 2025 | 5.99% |
| Sep 30, 2025 | 64.29% |
| Jun 30, 2025 | -11.13% |
| Mar 31, 2025 | -50.39% |
| Dec 31, 2024 | -80.68% |
| Sep 30, 2024 | -87.18% |
| Jun 30, 2024 | -128.55% |
| Mar 31, 2024 | -328.15% |
| Dec 31, 2023 | -196.47% |
| Sep 30, 2023 | -240.54% |
| Jun 30, 2023 | -316.40% |
| Mar 31, 2023 | -312.37% |
| Dec 31, 2022 | -291.67% |
| Sep 30, 2022 | -298.91% |
| Jun 30, 2022 | -279.28% |
| Mar 31, 2022 | -348.94% |
| Dec 31, 2021 | 56.10% |
| Sep 30, 2021 | -64.72% |
| Jun 30, 2021 | -71.34% |